Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options Phase II data show potential of efimosfermin to reverse liver ...

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) · Affecting up to 5% of the global ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Investing.com -- Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong ...

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options Phase II data show potential of efimosfermin to reverse liver ...